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Abstract
Background Acute Myeloid Leukemia (AML) bone mar-
row biopsies at diagnosis display enhanced angiogenesis
and increased VEGFA expression. In a xenograft mouse
model it was described that availability of free VEGFA
versus bound VEGFA is related to different vascular
morphology. In this study we investigate the relationship
between vascular morphology within AML bone marrow
biopsies and AML derived VEGFA levels.
Methods Vessel countandsurface area(Chalkleycount)were
calculatedinAMLbonemarrowbiopsiesatdiagnosis(n=32),
at remission (n=8) and Normal Bone Marrow (n=32) using
immunohistochemical staining for FVIII, CD31, CTIV, SMA
and VEGFA. VEGFA protein levels were measured.
Results High vessel count was associated with an immature
vessel status. Combining vessel count and Chalkley count
different vessel morphology patterns were quantified within
AML bone marrow biopsies. Three different subgroups
could be distinguished. The subgroup (37.5% of the
samples) exhibiting a high vessel count and vessels with
predominantly large lumen (normal Chalkley count) was
associated with high secreted VEGFA protein levels.
Conclusion Different vasculature patterns are seen in AML
bone marrow biopsies, defined by combining number and
size of vessel. These quantified morphology patterns,
combined with VEGFA levels, might be of value in the
success of VEGF/VEGFR-signaling interference
approaches.
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1 Introduction
Acute Myeloid Leukemia (AML) is a disease with a poor
outcome; the overall survival at 5 years is moderate to poor
depending on age and cytogenetics [3, 6, 12]. At diagnosis
an enhanced microvessel density (MVD) in bone marrow
biopsies has been observed, which is restored to normal
levels when a complete remission has been achieved [5,
21]. In addition, in AML patients a high bone marrow
blood flow and high tissue perfusion measured by MRI
techniques is related to a significantly decreased disease-
free survival and overall survival [14]. The enhanced bone
marrow vascularization is correlated with an increased
expression of Vascular Endothelial Growth Factor (VEGF)
A[ 5]. Moreover, the level of VEGFA is an independent
prognostic factor for treatment outcome in AML [1, 5].
Clinical trials targeting the VEGF/VEGFR signaling path-
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reported and showed beneficial effects in a subset of
patients. Treatment with Bevacizumab, a monoclonal
antibody against VEGFA, following chemotherapy
achieved a complete remission in 33% of patients with
refractory AML [18]. A VEGF receptor tyrosine kinase
inhibitor, SU5416, showed a significantly higher response
rate and reduction of bone marrow microvessel density in
patients with AML blasts expressing high levels of VEGF
mRNA than in patients with low VEGF expression [9].
These reports show that there is at least heterogeneity in
treatment response related to VEGFA levels.
Normal vasculature is highly organized and consists of
vessels formed by Endothelial Cells (ECs) which are
surrounded by basal membrane components and pericytes to
provide structural and functional support [4]. This mature
vasculature pattern is thought to be the result of a
coordinated balance between pro-angiogenic and anti-
angiogenic factors (reviewed in [10, 11]). In contrast to the
formation of normal blood vasculature, xenograft animal
models showed that tumor vasculature is structurally and
functionally abnormal; the hierarchical structure has been
lost and dilated vessels and/or angiogenic vessel sprouts
appeared [15, 23, 25]. The process of vessel formation
comprises a disturbance in the balance of angiogenic factors,
where VEGFA seems to play an important role [8]. These
kind of differences in tumor vessel morphology seemed to be
related to the availability of VEGFA; bound VEGFA results
in angiogenic sprouting, whereas free or cleaved VEGFA
results in dilated vessels in a xenograft mouse model [20].
In the present study we identified for the first time
different structured networks of vessels in the bone marrow
of newly diagnosed AML patients. Three different sub-
groups could be distinguished. In addition, one of the
subgroups containing a high vessel count and a high vessel
surface area was associated with high VEGFA protein level
secreted by AML cells.
2 Materials and methods
2.1 Leukemic cells and bone marrow biopsy specimens
Bone marrow biopsies and leukemic cells of 32 newly
diagnosed AML-patients were obtained at presentation after
informed consent in accordance with the regulations and
protocols sanctioned by the medical ethical committee.
Clinical and cell biological data, including (cyto-)genetics as
well as treatment outcome, were obtained from UMCG
patient database. Table 1 summarizes patient characteristics
of the AML patients. AML patients were treated following
Dutch Hemato-Oncology Group (HOVON) protocols. In
8 AML patients a bone marrow biopsy was available at the
time of complete remission. Normal control bone marrow
biopsies were obtained from patients who underwent bone
marrow biopsies as a staging procedure for a solid tumor or
hematological insufficiency (e.g. anemia, leucopenia) and
were diagnosed as normal (n=32). Mononuclear cells
(MNCs) were separated using Lymphoprep (Nycomed, Oslo,
Norway) density gradients and cryopreserved in liquid
nitrogen until use. Cryopreserved AML cells were thawed
rapidly at 37°C diluted in a 5× volume of normal calf serum
(NCS) as previously described [7]. The remaining pellet was
T cell-depleted by sheep red blood cells and separated over a
Lymphoprep density gradient. The remaining blast cell
population contained more than 95% AML cells and is
hereafter referred to as AML cells.
2.2 Culture conditions for leukemic cells
AML cells were cultured at 1×10
6 cells/ml in X-vivo 10
medium supplemented with penicillin/streptomycin for 24 h
(FCS, Hyclone, Logan, UT, USA). Supernatants were
harvested and centrifuged.
2.3 Detection of proteins using enzyme-linked
immunosorbent assay (ELISA)
Secretion of human VEGFA by AML cells was detected in
the supernatant using commercially available ELISAs
(Quantikine immunoassays, R & D, Minneapolis, MN,
USA) following the manufacturer’s instructions. VEGFA
levels were detectable in 11 of the 30 samples.
2.4 RNA extraction and quantitative RT-PCR
Total RNA of the AML cells was extracted with the
RNeasy mini kit according to the manufacturer’s descrip-
tion (Qiagen, Breda, the Netherlands). An on column
DNAse digestion was performed to purify the obtained
RNA. cDNA was prepared by reverse transcription as
described by the manufacturer (MBI Fermentas GmbH, St.
Leon-Rot, Germany). The final reaction mix had a final
volume of 20 μl and contained 1 μg total RNA, 1 μg
random hexamers, 1 mM of dNTPs, 20 U RNAse inhibitor
and 200 U of RevertAid™ M-MuLV Reverse Transcrip-
tase. Quantitative LightCycler PCR was performed using
the LightCycler-FastStart DNA Master SYBR Green I
system using 1 μl of a 10-fold diluted cDNA in each
PCR reaction in a final volume of 10 μl (Roche Molecular
Biochemicals, Mannheim, Germany). Specific primers for
β2-microglobulin were sense (CCA GCA GAG AAT GGA
AAG TC) and antisense (GAT GCT TAC ATG TCT CG),
PCR product 268 bp, 22 cycles, 55°C; for VEGFA sense
(GAG TGT GTG CCC ACT GAG GAG TCC AAC) and
antisense (CTC CTG CCC GGC TCA CCG CCT CGG
290 A.C. Weidenaar et al.CTT), PCR product 177, 312, 384 bp, 32 cycles, 60°C.
PCR products were subjected to melting curve analysis
using the Light Cycler system to exclude the amplification
of unspecific products. Finally, the PCR products were
analyzed by conventional agarose gel electrophoresis. The
expression of VEGF was standardized for expression of β2-
microglobulin (Arbitrary Units, AU). Serial cDNA dilu-
tions of a mixture of all patient samples were used to
generate standard curves. The expression of each gene in
each sample was analyzed in duplicate. The regression
coefficients of the standard curves were ≥0.99.
2.5 Immunohistochemical analysis
Bone marrow paraffin biopsy specimens were cut into 4-
μm sections and stained for Factor VIII related antigen
(FVIIIRA, also known as von Willebrand Factor), Collagen
type IV (CTIV), CD31, SMA and VEGFA. Sections were
deparaffined, blocked for endogenous peroxidase with
0.3% H2O2, blocked for antigen retrieval with 1% protease,
immunostained for FVIIIRA (DAKO, AS, Glostrup, Den-
mark) and amplified with biotin-streptavidin HRPO
(DAKO). The sections stained with CD31 (DAKO), SMA
(DAKO) and CTIV (Southern Biotech, Birmingham,
Alabama, USA) were treated the same way except for the
antigen retrieval with 0.1 M Tris-HCl pH 9.0 at 80°C over
night (SMA) or for 30 min in the microwave (CD31,
CTIV). VEGFA (Santa Cruz, Heidelberg, Germany) stain-
ings were blocked with 0.1 M Tris-HCl pH 9.0 for 15 min
in the microwave and treated with an avidine/biotine block.
The color reaction was assessed by adding substrate for
peroxidase. After that the slides are colored with hematox-
illin. Negative controls were produced by using non-
specific IgG as the primary antibody (DAKO).
Characteristic AML patients Normal bone marrow AML remission
No. 32 32 8
Age at diagnosis, y 54 (20–73) 58 (17–83) 48 (20–64)
Sex, male/female 17/15 17/15 4/4
White blood cell count (x 10
9/L) 28 (8–269)
Peripheral blasts (%) 62 (3–97)
Platelets (x 10
9/L) 48.7 (1.1–241.0)
Cytogenetics, n (%)
Favorable 2 (6)
Intermediate 18 (56)
Unfavorable 4 (13)
Not available 8 (25)
SCT
No SCT 22
Allogeneic SCT 7
Autologous SCT 3
Cycles to CR, n (%)
1 13 (41)
2 9 (28)
3 2 (6)
No CR 8 (25)
Relapse, n (%) 18 (56)
Dead/alive 24/8
Staining
Vessel count, n (%) 32 (100) 32 (100) 8 (100)
counts 16.2 (5.8–33.8) 7.4 (2.0–15.0) 5.7 (1.0–9.8)
Chalkley count, n (%) 32 (100) 32 (100) 8 (100)
counts 5.4 (3.2–11.0) 5.3 (3.3–10.3) 7.5 (6.0–10.0)
%CTIV-positive vessels, n (%) 29 (91) 28 (88) 7 (88)
counts 87.3 (2.0–100.0) 100.0 (0.0–100.0) 61.2 (0.0–100.0)
%SMA-positive vessels, n (%) 26 (81) 31 (97) 8 (100)
counts 35.0 (8.9–100.0) 73.1 (22.7–100.0) 54.9 (18.4–100.0)
VEGFA, n (%) 32 (100) 13 (41) 8 (100)
Table 1 Patient characteristics
Characteristics—age, WBC,
percentage peripheral blasts and
platelets— and staining counts
are given as median (range)
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using light microscopy in areas of the slide containing the
highest numbers of blood vessels (hotspots). After the
hotspots were identified, the total number of vessels per
selected image was counted at × 400 magnification. At least
five fields were counted for each section, and the true
vessel number was expressed as the mean of five counts.
Quantification of the relative area estimate of the vessels
was assessed using the Chalkley point overlap morphomet-
ric technique as described before [22, 24]. This method
entails the use of an ocular grid with 25 random points. The
ocular grid was turned to maximize the overlap between
points on the grid and the vessels for five hotspots at 400 ×
magnification. The number of overlapping points was
counted for each of the hot spots, and the Chalkley count
was expressed as mean value of the five counts. The
Chalkley count was determined on FVIIIRA, CD31 and
CTIV staining with a correlation coefficient of rho = 0.714,
p=0.001. Biopsies of 6 AML-patients and 1 normal bone
marrow control could not be evaluated for SMA. Pericyte
coverage (%SMA-positive vessels) and basal membrane
coverage (%CTIV-positive vessels) were expressed as the
percentage of FVIII positive vessels. The intensity of the
VEGFA staining was analyzed semiquantitatively: 0 = no
staining, 1 = slight staining, 2 = moderate staining, 3 =
maximal staining. All stainings were evaluated by at least
two separate investigators who had no knowledge of patient
characteristics. Data was summarized in Table 1.
2.6 Statistical analysis
Statistical analysis was performed with PASW Statistics 18.
Thesignificanceofchangesinvesselcounts,%SMA-positive
vessels, VEGFA production and patient characteristics be-
tweenthreedefinedmorphologygroupsorcytogeneticgroups
wasassessedusingnon-parametrictests(KruskalWallisTest).
The % SMA-positive vessels between two groups, and the
correlation between vessel count and sex were determined
with the non-parametric Mann Whitney-U test. Correlation
between vessel count and patient characteristics was mea-
sured using the Spearman’s rho. Correlation between vessel
count and Chalkley count for the AML biopsies at diagnosis
was measured using the Spearman’s rho. A significant
difference was defined as a p-value≤0.05.
3 Results
3.1 Immature vessel status in AML bone marrow biopsies
at diagnosis
Vessel count was significantly (p<0.001) increased in AML
bone marrow at diagnosis (median: 16.2 microvessels/hpf,
range 5.8–33.8, n=32) compared with normal control bone
marrow (NBM, median: 7.4 microvessels/hpf, range 2.0–
15.0, n=32), and returned to normal levels when complete
remission was achieved (median: 5.7 microvessels/hpf, range
1.0–9.8, n=8) underscoring previous studies (Fig. 1a)[ 5,
21]. Based on the fact that >95% of the Normal Bone
Marrow biopsies and AML remission biopsies had a vessel
count below 13 microvessels/hpf, it appeared that a higher
vessel count was aberrant. Therefore, the value of 13
microvessels/hpf was taken as cut-off point for categoriza-
Fig. 1 Bone marrow vessel count and pericyte coverage in AML (a)
Boxplot of vessel count in AML bone marrow compared with normal
bone marrow and AML remission. Vessel count in bone marrow
biopsies of AML patients is significantly (p<0.001) higher than in
NBM or AML remission group. Median values are represented by a
bar in the boxplot. (b) Boxplot of percentage SMA-positive vessels in
bone marrow biopsies of newly diagnosed AML patients, normal
controls and AML patients in remission. Pericyte coverage is
significantly (p<0.001) lower in bone marrow biopsies of AML
patients at diagnosis. Median values are represented by a bar in the
boxplot
292 A.C. Weidenaar et al.tion into ‘low vessel count’ (13 or less) and ‘high vessel
count’ (more than 13). Of the AML bone marrow biopsies
75% (24/32) were categorized as biopsies with a ‘high vessel
count’. No significant correlation was found between vessel
count and patient characteristics such as WBC count (p=
0.65, Spearman’sr h o :−0.08,), platelets (p=0.85, Spearman’s
rho: 0.04), blast percentage at diagnosis (p=0.27, Spear-
man’sr h o :−0.16), and age (p=0.67, Spearman’sr h o :0 . 0 8 ) ,
and no significant difference in vessel count was found for
cytogenetics (p=0.27, Kruskal-Wallis test) and sex (p=0.58,
Mann Whitney U test).
Basal membrane surrounding of the vessels was deter-
mined by the percentage collagen type IV (%CTIV)
positive vessels. Median value in the AML bone marrow
biopsies was 87.3% (range 2.1–100.0%, n=29) compared
with 100.0% in the NBM (range 0.0–100.0%, n=28) and
61.2% in the AML remission bone marrow biopsies (range
0.0–100.0%, n=7). No significant difference was found
between the groups, suggesting that the number of
endothelial cell structures surrounded by basal membranes
is comparable. Since vessel stabilization requires pericyte
coverage of the vascular sprouts, we studied the number of
vessels positive for Smooth Muscle Actin (SMA), a marker
for pericytes. In AML bone marrow biopsies at diagnosis
35.0% of vessels were pericyte-coated (range 8.9–100.0%,
n=26) versus 73.1% of vessels in the NBM (range 22.7–
100.0%, n=31) and 54.9% in the AML remission group
(range 18.4–100.0%, n=8) (p<0.001, Fig. 1b). Interesting-
ly, the percentage vessels coated with pericytes was
significantly (p=0.04) higher in the ‘low vessel count’
group (45%, range 23–100%, n=7) compared with the
biopsies with ‘high vessel count’ (29%, range 9–57%, n=
19), indicating that high vessel count in AML bone marrow
is related to a more immature vessel status.
3.2 Different vasculature morphology patterns within AML
bone marrow biopsies at diagnosis
Assessing vessel morphology it appeared that different
vasculature patterns within the AML bone marrow biopsies
were seen (Fig. 2); biopsies displaying a high number of
vessels with predominantly a large lumen and thin walls,
but also biopsies exhibiting a high vessel count with mainly
a network of small vessels with thin walls, narrow lumen
and branching. To quantify this observation the vessel
count was combined with a method to measure the vessel
surface area, the Chalkley count; this is a quantification
technique which determines a number of grid points that hit
stained vessels or lumina. Figure 3 shows the results for
vessel count and Chalkley count for the AML biopsies at
diagnosis (median Chalkley count: 5.4, range 3.2–11.0),
Normal Bone Marrow samples (median Chalkley count:
5.3, range 3.3–10.3) and AML at remission (median
Chalkley count: 7.5, range 6.0–10.0). Within the group
displaying a ‘high vessel count’ we further categorized the
biopsies into two subgroups. The median value of 5.4 was
taken as a cut-off for categorization into ‘low’ (5.4 or less)
and ‘high’ (more than 5.4) Chalkley count. The first
subgroup (12/32, 37.5%) had a high Chalkley count (group
Ii nF i g .3) and was defined as’vessel hyperplasia’,
characterized by vessels with a predominantly large lumen
and thin walls. The second subgroup (12/32, 37.5%) had a
low Chalkley count (group II in Fig. 3) and was defined as
‘angiogenic sprouting’, displaying a network of small
vessels with thin walls, narrow lumen and branching.
Regarding patient characteristics the number of platelets at
diagnosis was significantly (p=0.02) higher in the ‘vessel
hyperplasia’ patients compared with the other two defined
morphology patterns (data not shown). No differences were
found between the morphological identified subgroups and
other patient characteristics.
3.3 High free VEGFA levels excreted by AML cells related
to vessel hyperplasia morphology
In a xenograft mouse model the availability of free versus
bound VEGFA was related to the appearance of the tumor
vasculature [20]. Since AML cells can secrete VEGFA we
hypothesized that the observed differences in AML bone
marrow vessel morphology could be related to excreted
VEGFA protein levels. Immunohistochemical staining for
total VEGFA protein expression showed a diffuse VEGFA
distribution in all AML biopsies at diagnosis: the cytoplasm
of leukemic blasts as well as the intercellular areas were
mainly positive for VEGFA (Fig. 2). In contrast, Normal
Bone Marrow biopsies showed a different distribution
pattern, similar to biopsies of patients in complete remis-
sion: highly positive myeloid cells, a positive cytoplasm of
megakaryocytes and erythroid cells that were negative for
VEGFA (not shown). Immunohistochemistry (IHC) of the
AML biopsies at diagnosis showed that the total amount of
protein VEGFA was comparable in all samples. In
accordance with the IHC the VEGFA mRNA level was
not significantly (p=0.24) different within the three defined
subgroups (‘low vessel count’ 3.1 AU, range 2.0–13.1;
‘vessel hyperplasia’ 6.1 AU, range 2.0–49.3; ‘angiogenic
sprouting’ median 15.1 AU, range 2.6–64.6). In contrast,
AML derived excreted VEGFA protein levels in AML at
diagnosis were significantly (p=0.007) higher in the ‘vessel
hyperplasia’ morphology subgroup compared to the ‘an-
giogenic sprouting’ subgroup and the ‘low vessel count’
biopsies (Fig. 4) (median 2.00 pg/ml, range 2.00–47.77, n=
30). Overall, we conclude that the total amount of VEGFA
protein level and mRNA is similar in the AML biopsies at
diagnosis whereas AML derived VEGFA levels are higher
in the group displaying a’vessel hyperplasia’ pattern.
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Over the past years it has become clear that new vessel
formation is part of the ongoing process in AML; MVD is
increased in bone marrow biopsies of patients with newly
diagnosed AML compared with normal bone marrow
biopsies [5, 21]. In our study we distinguished vessel
heterogeneity in AML bone marrow biopsies at diagnosis.
Using vessel count and Chalkley count we were able to
divide the AML bone marrow biopsies at diagnosis into
three subgroups: a subgroup with a ‘low vessel count’,a
subgroup called ‘angiogenic sprouting’ (high vessel count,
low Chalkley count) and a subgroup ‘vessel hyperplasia’
(high vessel count, high Chalkley count). To our knowl-
edge, this is the first study that describes different
quantified vasculature patterns in AML.
Fig. 2 Morphology patterns in
AML bone marrow biopsies.
Dilated vessels in panel a and
sprouting vessels in panel b.
Representative pictures of bone
marrow immunohistochemistry
for FVIII, CTIV and VEGFA
(×400)
294 A.C. Weidenaar et al.In solid tumors, the morphology of vessels has been
studied extensively. It shows that microvessels are not
hierarchically structured and can consist of dilated vessels
and/or angiogenic vessel sprouting [2]. These vasculature
characteristics of solid tumors compromise the delivery and
effectiveness of conventional cytotoxic therapies [16].
Treatment with VEGF/VEGFR-signaling interfering drugs
induce a ‘normalized’ vessel pattern as described by vessel
remodeling and increased pericyte coverage of tumor vessels
[13, 17]. As a result vessel stabilization and reduced
permeability is achieved, facilitating a more efficient delivery
of drugs to the targeted cancer cells. In our study we found
that a high vessel count in AML bone marrow biopsies is
related to a more immature vessel status, implicating that
normalization of the vasculature might improve the outcome
of chemotherapeutic drugs coadministered.
Drugs targeting VEGF/VEGFR signaling are promising
in the treatment of cancer, with an immature vasculature
within the tumor being more susceptible. This study shows
that AML bone marrow biopsies have a high number of
vessels, related to a low percentage of pericyte coverage.
Recently, a clinical trial with Bevacizumab, a monoclonal
antibody that binds VEGFA, following chemotherapy
showed a favorable Complete Remission rate and duration
in relapsed and refractory AML [18]. However, heteroge-
neity in the treatment response was seen during this trial.
Since we describe differences in AML vasculature related
to VEGFA levels the question raises: do different morphol-
ogy patterns in AML bone marrow warrant distinct
therapeutic approaches, thereby increasing the response?
Ongoing work investigating the response of anti-VEGFA
therapies related to AML bone marrow vasculature will
have to answer this question.
In a xenograft mouse model the appearance of ‘vessel
hyperplasia’ and ‘angiogenic sprouting’ was demonstrated
and seemed to be related to the availability of VEGFA [20].
VEGFA can be released via breakdown of the Extracellular
Matrix (ECM). This cleaved variant of VEGFA mainly
produces dilated vessels. When VEGFA is not cleaved, and
therefore not released from the ECM, it results in an
angiogenic sprouting profile [20]. In corroboration with the
abovementioned study we showed that biopsies with a high
vessel count and a high Chalkley count were related to
elevated AML blast derived VEGFA in vitro whereas
‘angiogenic sprouting’ and ‘low vessel count’ showed a
relative low VEGFA level in vitro. These results support the
view that the amount of free VEGFA could play a role in
vascular patterning in AML. Interestingly, we also found
that patients in the ‘vessel hyperplasia’ subgroup had a
significantly higher platelet count at diagnosis compared
with the other two defined subgroups. Since platelets can
release VEGFA in vivo, an even higher VEGFA level can
be expected enlarging vessel differences even more [19].
In conclusion, our study shows that heterogeneity in
AML bone marrow vasculature can be quantified using
Chalkley count in addition to vessel count and that biopsies
displaying a high vessel count with low pericyte coverage
Fig. 4 Relation between AML derived VEGFA protein levels and
vessel morphology in AML at diagnosis. The AML-excreted VEGFA
protein level was significantly (p=0.007) higher in the subgroup with
a ‘vessel hyperplasia’ morphology compared with the’angiogenic
sprouting’ or the ‘low angiogenic profile’. Box-and-whisker plot
limits depict 75th and 25th percentiles and median value (box), and
upper/lower quantile ± 1.5 × (interquantile range) (upper and lower
whiskers, respectively)
Fig. 3 Scatterplot representing the biopsies of AML at diagnosis, at
remission and Normal Bone Marrow. AML biopsies at diagnosis with
a ‘low vessel count’ are displayed below the Y-axis reference line (13
microvessels/hpf), based on the fact that >95% of Normal Bone
Marrow and AML remission biopsies had a vessel count below 13
microvessels/hpf. The X-axis reference line divides AML biopsies at
diagnosis with a ‘high vessel count’ into two subgroups according to
the median Chalkley count of 5.4 in AML at diagnosis and the
identical cut-off point set by the median Chalkley count of the NBM
and AML remission biopsies. Samples with a Chalkley count >5.4
were defined as ‘vessel hyperplasia’ (group I) and samples ≤5.4 as
‘angiogenic sprouting’ (group II). AML biopsies: Spearman’s rho
0.15, p=0.42
AML Vasculature Patterns Related to VEGFA Secretion 295could be diverted in two separate entities. Further studies
will help to clarify its usefulness for adapting therapeutic
approaches in trials with antiangiogenic or VEGFA-
blocking drugs.
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